Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Company Achieves Milestones in Both Clinical ProgramsInitiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by...
Coronavirus
Ainos Reports Third Quarter 2024 Financial Results
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and...
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering...
Services PMI® at 56%; October 2024 Services ISM® Report On Business®
Business Activity Index at 57.2%; New Orders Index at 57.4%; Employment Index at 53%; Supplier Deliveries Index at 56.4% TEMPE,...
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
SEATTLE WA AND LUND, SWEDEN / ACCESSWIRE / October 29, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) and Alligator Bioscience AB...
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present...
NanoViricides President Dr. Diwan to Present at the PODD Conference
SHELTON, CT / ACCESSWIRE / October 22, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage...
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,...
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
CALGARY, Alberta, Oct. 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader...
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage...
Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine
ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization...
XORTX Initiates Precision Medicine Program
Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine MetabolismCALGARY, Alberta, Oct....
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT /...
Services PMI® at 54.9%; September 2024 Services ISM® Report On Business®
Business Activity Index at 59.9%; New Orders Index at 59.4%; Employment Index at 48.1%; Supplier Deliveries Index at 52.1% TEMPE,...
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
NIAID will be conducting and sponsoring clinical trials to accelerate and to streamline the rapid development of next-generation COVID-19 vaccinesABINGDON,...
Manufacturing PMI® at 47.2%; September 2024 Manufacturing ISM® Report On Business®
New Orders and Backlogs Contracting; Production and Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Contracting; Customers' Inventories About Right; Prices...
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company...
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial – Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has...